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Beinwellwurzel: Von der Tradition zu modernen 
klinischen Studien 
Zusammenfassung Die arzneiliche Verwendung von 
Beinwellwurzel hat eine jahrhundertealte Tradition. 
Heute belegen zahlreiche randomisierte klinische Prü-
fungen die Wirksamkeit und Sicherheit. Beinwellwur-
zelextrakt wird äußerlich angewendet zur Behandlung 
von schmerzhaften Muskel- und Gelenkbeschwerden. 
Schmerzen, Entzündungen und Schwellungen bei Knie-
gelenksarthrose degenerativen Ursprungs und akute 
Myalgien im Bereich des Rückens gehören ebenso zu 
den klinisch belegten Anwendungsgebieten wie Ver-
stauchungen, Prellungen und Zerrungen nach Sport- 
und Unfallverletzungen, auch bei Kindern ab 3 Jahren. 
Der Artikel gibt eine aktuelle Übersicht über klinische 
Prüfungen, nicht-interventionelle Studien und weitere 
Literatur zu Beinwellwurzel.
Schlüsselwörter: Übersicht, Symphytum officinale L., 
Beinwellwurzel, Klinische Studie, Nicht-interventionelle 
Studie, Wirksamkeit, Sicherheit
Summary Comfrey (Symphytum officinale L.) has 
been used over many centuries as a medicinal plant. 
In particular, the use of the root has a longstanding 
tradition. Today, several randomised controlled trials 
have demonstrated the efficacy and safety. Comfrey 
root extract has been used for the topical treatment 
of painful muscle and joint complaints. It is clinically 
proven to relieve pain, inflammation and swelling of 
muscles and joints in the case of degenerative arthri-
tis, acute myalgia in the back, sprains, contusions and 
strains after sports injuries and accidents, also in chil-
dren aged 3 years and older. This paper provides in-
formation on clinical trials, non-interventional stud-
ies and further literature published on comfrey root 
till date.
Keywords: Review, Symphytum officinale L., Comfrey 
root, Clinical trial, Non-interventional study, Efficacy, 
Safety
Introduction
Comfrey root has been used as a traditional medicinal 
plant for the treatment of painful muscle and joint com-
plaints for centuries [1, 2]. Native in Europe, the plant has 
an impressive record of medicinal use. It also naturalised 
in Northern America, where it rapidly spread. Native 
Americans recognised the healing powers and included 
comfrey root in their therapeutic armamentarium [3–5]. 
A recent text book chapter gives detailed information on 
botanical aspects and harvesting of the plant [6].
The key activity-determining constituents of comfrey 
root extracts and its molecular mechanisms of action 
have not been completely elucidated. Allantoin and ros-
marinic acid are probably of central importance for its 
pharmacodynamic effects [7]. The German Commission 
E [8] has assessed Symphyti radix (comfrey root) deriving 
from Symphytum officinale L. positively for the external 
use in bruises, strains and sprains and acknowledged its 
actions as anti-inflammatory, antimitotic and promotion 
of callus formation.
Further, a European Scientific Cooperative on Phy-
totherapy Monograph (ESCOP) is available for comfrey 
root [9]. The monograph mentions strains, contusions 
and distortions, osteoarthritis (OA), epicondylitis, ten-
dovaginitis and periarthritis as therapeutic indications 
substantiated by clinical trials. ESCOP states that com-
frey root has also been used for tendinitis syndrome, 
knee joint injuries, non-active gonarthrosis, insect bites, 
mastitis, fractures and skin inflammation, although pub-
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lished scientific evidence does not yet adequately sup-
port these indications.
Randomised clinical trials
The medicinal use of preparations from the underground 
parts of the plants (Symphyti radix) is well established. 
Till date, comfrey root extract preparations have been 
marketed in more than ten countries. Most recently, a 
cream has also been launched in Austria. Randomised 
clinical trials and non-interventional studies studied the 
efficacy of comfrey root extract ointment for the treat-
ment of various muscle and joint complaints [10].
Back pain
Back pain, especially of the upper and lower back, is a 
widespread condition impairing quality of life and func-
tional movement in a large number of individuals. The 
treatment strategy has recently also adopted a direct 
anti-inflammatory topical approach, mostly with chemi-
cal non-steroidal anti-inflammatory drugs (NSAIDs). 
This approach has been intensively used and has proved 
to be efficacious in the management of symptoms, thus 
reducing pain, facilitating rehabilitation and achieving 
earlier recovery. Comfrey root as a herbal ingredient can 
contribute in the same way, as it is also known for its anti-
inflammatory properties.
A double-blind, placebo-controlled, multi-centre, 
randomised clinical trial with parallel group design was 
conducted over a period of 5 days [11]. Total 120 patients 
with acute upper or lower back pain used either a verum 
cream containing comfrey root fluid extract (1:2, 35.0 g, 
extraction solvent ethanol 60 % (v/v), less than 0.35 ppm 
of pyrrolizidine alkaloids) or a corresponding placebo. 
They were treated three times a day, 4 g per application. 
The trial included four visits and was performed at the 
Deutsche Sporthochschule in Cologne and three addi-
tional ambulatory centres for orthopaedics and sports 
medicine.
The primary efficacy variable was the area under the 
curve (AUC) of the visual analogue scale (VAS) on active 
standardised movement values at first to fourth visit. 
Patients performed standardised, muscle group-specific 
tests to assess the pain intensity on VAS. Secondary objec-
tives were back pain at rest, pressure algometry, global 
assessment of efficacy by the patient and the investigator, 
intake of analgesic medication and functional impair-
ment measured using the Oswestry Disability Index.
The results showed a significant treatment differ-
ence between comfrey root extract and placebo regard-
ing the primary variables. The pain intensity on active 
standardised movement decreased on average (median) 
approximately 95.2  % in the comfrey extract group 
(104.8–12.7 mm (mean VAS sum)) and 37.8 % in the pla-
cebo group (100.0–56.5 mm (mean VAS sum); p < 0.001). 
Also, in all secondary parameters, the superiority of the 
verum treatment compared with placebo was significant 
(each p < 0.001). Both the AUC of the reported back pain 
at rest, the AUC of the pressure algometry in the trigger 
point as well as the global assessment of the efficacy 
by the patients and the investigators showed a clini-
cally relevant effect in reducing acute back pain. For the 
first time, also a fast-acting effect of the ointment (1  h) 
was witnessed. After 1  h the pain intensity was already 
decreased about 33.0  % in the comfrey group (104.8–
60.4  mm (mean VAS sum)) and 12.0  % in the placebo 
group (100.00–86.5 (mean VAS sum)) indicating an early 
onset of the treatment effect. Four patients in the comfrey 
extract group and three in the placebo group experienced 
adverse events in the course of the clinical trial. Eczema, 
cold, nausea and rhinitis occurred in the verum group, 
headache (n = 2) and pruritus in the placebo group. All 
adverse events were of mild severity. One comment on 
the trial asked for more data in patients with different 
sorts of other back pain, but admits that the results are 
relevant and topical treatment is increasingly considered 
as a serious treatment option [12].
Osteoarthritis (OA)
The same comfrey root extract cream was investigated in 
a randomised, double-blind trial including 220 patients 
suffering from painful OA of the knee [13]. OA character-
ises a primarily non-inflammatory, degenerative change 
of the structure of the cartilage and bones of one or more 
joints, involving an increasing deformation of the joint. 
On principle, all joints can be affected; most frequently 
knee and hip joints, hands and the spine. As age is one 
of the strongest risk factors for OA of all joints, the fre-
quency of OA rises with age [14]. Approximately, 80 % of 
people more than 75 are affected. Symptomatic improve-
ment represents an important therapeutic objective. The 
reduction of pain, the preservation and the restoration 
of the joint’s function and thus the restoration of quality 
of life are therefore important target parameters. Again, 
topical treatment is one further option besides oral 
medication.
All patients in this clinical trial met the criteria of 
the American College of Rheumatology. They received 
2  g of either the active or a corresponding placebo 
cream three times daily, for 21 days. In self-medication, 
pain, functional impairment and stiffness are the most 
important symptoms patients seek to relieve. There-
fore, the primary target variable was the VAS sum score 
of pain at rest and pain on movement. Secondary tar-
get variable was the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) score. The 
total score of the primary target variable decreased 
by 51.6 mm (54.7 %) in the verum group and 10.1 mm 
(10.7 %) in the placebo group, a significant difference of 
41.5 mm (44.0 %) between groups (p < 0.001). The sec-
ondary target criterion reduced by 60.4 mm (58.0 %) in 
the verum group and 14.7 mm (14.1 %) in the placebo 
group during the course of the study, the difference of 
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45.7  mm (43.9  %) being again significant (p < 0.001). 
Superiority of improvement in the verum group was 
also evident with respect to four explorative second-
ary parameters: SF-36 (quality of life), angle measure-
ment (mobility of the knee), clinical global impression 
(CGI) and global assessment of efficacy by physicians 
and patients (p < 0.001 for each parameter). A total of 
22 adverse events (AE) occurred in 22 patients (7 in the 
active therapy group, 15 in the placebo group). None did 
represent an adverse drug reaction in the active therapy 
group.
Usually, the production of placebos for herbal drugs 
is associated with difficulties. However, one comment on 
the trial emphasized that due to the low inherent smell of 
the extract and the same perfume used in both placebo 
and verum, a very good blinding could be achieved for 
this preparation [15]. Another comment found the trial to 
be well conducted and in accordance with theGCP-ICH-
guidelines and sees the short-term use of the preparation 
to be a useful treatment option free of serious adverse 
reactions [16].
Another recent trial investigated two concentrations 
of topical, comfrey-based botanical creams containing a 
blend of tannic acid and eucalyptus to a eucalyptus ref-
erence cream on pain, stiffness and physical functioning 
in those with primary OA of the knee [17]. Total 43 male 
and female subjects (45–83 years old) with diagnosed 
primary OA of the knee who met the inclusion criteria 
were randomly assigned to treatment groups: 10 or 20 % 
comfrey root extract (Symphytum officinale L.) or a pla-
cebo cream. Outcomes of pain, stiffness and functioning 
were measured on the WOMAC. Participants applied the 
cream three times a day for 6 weeks and were evaluated 
every 2 weeks during the treatment. Repeated-measures 
analyses of variance yielded significant differences in all 
of the WOMAC categories (pain p < 0.01, stiffness p < 0.01 
and daily function p < 0.01), confirming that the 10 and 
20  % comfrey-based creams were superior to the refer-
ence cream. The active groups each had two participants 
who had temporary and minor adverse reactions of skin 
rash and itching, which were rapidly resolved by modi-
fying applications. Authors concluded that both active 
topical comfrey formulations were effective in relieving 
pain and stiffness and in improving physical functioning 
and were superior to placebo in those with primary OA of 
the knee without serious adverse effects.
Blunt injuries
A further trial with a combination of standardized com-
frey extract (200 mg/g), tannic acid (100 mg/g) plus other 
ingredients including aloe vera gel (300 mg/g), eucalyp-
tus oil (40 mg/g), and frankincense oil (1.0 mg/g) assessed 
the efficacy of thrice daily topical treatment on osteoar-
thritic knee pain, markers of inflammation and cartilage 
breakdown over 12 weeks [18]. Adults aged 50–80 years 
(n=133) with clinical knee OA received verum or placebo 
in addition to existing medications. Pain and function 
were measured using a VAS and the Knee Injury and 
Osteoarthritis Outcome Score (KOOS) scale at baseline, 
4, 8 and 12 weeks. Inflammation was measured analysing 
IL-6 expression and CTX-2 presence as representative 
for cartilage breakdown using ELISA, at baseline and 12 
weeks. Although the paper does not specify the part of the 
comfrey plant used in the extract, the drug extract ratio or 
the nature of standardization, it refers to the same commer-
cial product as Smith and Jacobson [17]. Pain scores were 
significantly lower in the verum group compared to pla-
cebo after 12 weeks using both the VAS (–9.9 mm, p = 0.034) 
and the KOOS pain scale (+5.7, p = 0.047). Changes in 
IL-6 and CTX-2 were not significant (–0.04, p = 0.5; –0.01, 
p = 0.68). In a post-hoc analysis, the authors suggested 
that treatment may be most effective in women (VAS 
–16.8 mm, p = 0.008) and those with milder radiographic 
OA (VAS –16.1 mm, p = 0.009). They concluded that the 
topical comfrey combination with tannic acid is a safe 
and effective treatment for the symptoms of knee OA 
in participants with moderate knee pain, and clinical 
OA. The treatment reduced pain and increased muscle 
strength, but had no effect on systemic inflammation or 
cartilage breakdown over 12 weeks of treatment.
Comfrey root has a strong historical record in the 
treatment of blunt injuries due to its anti-inflammatory, 
de-swelling and pain-relieving properties. The efficacy 
granted by the Commission E has been further substan-
tiated with clinical data. The percutaneous efficacy of 
the cream with the afore-mentioned comfrey root fluid 
extract (1:2, 35.0 g, extraction solvent ethanol 60 % (v/v)) 
was confirmed in a clinical trial on patients suffering 
from ankle distortion [19, 20]. The double-blind, multi-
centre, randomised, placebo-controlled, group compari-
son included 142 patients with a mean age of 31.8 years; 
among them 78.9  % were male. The inclusion criterion 
was an uncomplicated, acute unilateral ankle distortion 
that had been endured no longer than 6  h previously. 
The duration of treatment was 8 days. The afflicted ankle 
was topically treated with c. 2 g (corresponding to a 6 cm 
strand of cream) of either verum or placebo.
The primary variable, tenderness of the ankle joint, 
was measured by pressure algometry, meaning the dif-
ference in tolerated pressure between injured and 
healthy ankles. Under active treatment, no adverse drug 
reactions were reported. During the course of treatment, 
pain regressed significantly more in the comfrey extract 
group than in the placebo group (p < 0.0001) and at the 
final assessment the reductions in tenderness compared 
with initial values were 2.44 kp/cm2 in the verum group 
compared with only 0.95  kp/cm2 in the placebo group. 
Compared with placebo, superiority of the verum treat-
ment was significant with regard to reduction in pres-
sure pain (tonometric method, p < 0.0001), ankle oedema 
(figure-of-eight method, p = 0.0001), ankle mobility (dor-
siflexion, p = 0.002; plantar flexion, p = 0.0116) and global 
efficacy (p < 0.0001).
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Verum-controlled versus diclofenac
For comfrey root, also a verum-controlled clinical trial 
versus topical diclofenac was performed. In a single-
blind, controlled, randomised, parallel groups, multi-
centre and confirmatory clinical trial outpatients with 
acute unilateral ankle sprains (n = 164) received either a 
6 cm-long ointment layer of the above-mentioned com-
frey root extract cream (n = 82) or of diclofenac gel con-
taining 1.16  g of diclofenac diethylamine salt (n = 82) 
[21]. The patients applied the cream four times a day for 
7 days.
The primary efficacy variable was pain arising from 
pressure on the injured area, measured with a calibrated 
algometer on days 0, 4 and 7 and evaluated by the AUC 
of the pain-time curve. Secondary variables were the 
circumference of the joint (swelling, figure-of-eight 
method), the individual spontaneous pain sensation at 
rest and at movement according to a VAS, the global effi-
cacy evaluation, the global assessment of tolerability and 
further variables. It was confirmatorily shown that com-
frey extract is non-inferior to diclofenac.
The 95  % confidence interval for the AUC (comfrey 
extract minus diclofenac gel) was 19.08–103.09 h*N/cm2 
and completely above the margin of non-inferiority. 
After 7 days of treatment, a mean relative reduction in 
VAS at rest of 92 % was found in the comfrey cream group. 
The corresponding reduction in the diclofenac group was 
85 %. The mean relative reductions in VAS in motion were 
83.2 % for comfrey extract and 72.4 % for diclofenac. The 
ankle swelling was decreased by 79.5  % in the comfrey 
root and 69.4 % in the diclofenac group. The pain on pres-
sure measured with an algometer was reduced by 80.6 % 
in the comfrey root, but only by 74.7 % in the diclofenac 
group.
A re-evaluation of the trial data in accordance with 
CPMP-guidelines [22] revealed even a superiority of the 
herbal in several parameters [23]. In the primary variable, 
the comfrey root extract cream showed a statistically sig-
nificant superiority above the diclofenac gel (p = 0.0012). 
On day 4, a statistically significant reduction of the pain 
on pressure (p = 0.0449), and on day 4 (p = 0.0368) and 
day 7 (p = 0.0074) a statistically significant reduction of 
the pain on movement was recorded. Further, the physi-
cians (p = 0.0130) as well as the patients (p = 0.0111) rated 
the global efficacy of the comfrey preparation signifi-
cantly higher than the efficacy of the diclofenac gel.
Diclofenac and other NSAIDs are well known for their 
side effects and upper gastrointestinal (GI) toxicity. There 
is also documented data regarding their adverse effects 
on lower GI tract such as colonic strictures, inflammatory 
bowel disease and complications of diverticular disease 
in the form of abscess or perforation. Therefore, patients 
and physicians seek for therapeutic alternatives. The 
findings of this clinical trial substantiates comfrey root 
extract as a good and efficient option for alternative topi-
cal treatment.
Combination with methyl nicotinate
A topical combination of 35 % comfrey root extract plus 
1.2  % methyl nicotinate was compared versus a single 
preparation of methyl nicotinate or placebo cream for 
relief of acute upper or lower back pain [24] in a ran-
domised, multi-centre, double-blind, three-arm, pla-
cebo-controlled trial. Total 379 patients were randomly 
assigned to three groups (combination, n = 163; methyl 
nicotinate, n = 164 and placebo, n = 52). They applied a 
12 cm layer of cream three times daily for 5 days. The pri-
mary efficacy variable was the AUC of the VAS on active 
standardised movement values at first to fourth visit. 
Secondary measures included back pain at rest, pressure 
algometry, consumption of analgesic medication, func-
tional impairment measured with Oswestry Disability 
Index and global assessment of response.
The AUC of the VAS on active standardised move-
ment was markedly smaller in the combination treat-
ment group than in the methyl nicotinate and in the 
placebo group (ANOVA: p < 0.0001). The pair-wise com-
parisons of the mean AUCs of VAS sums on active stan-
dardised movement showed values 27 % lower in favour 
of the combination compared with methyl nicotinate 
(6548.65  mm × h versus 8975.32  mm × h, i.e. a mean 
treatment effect of − 2426.7  mm × h), and values 50  % 
lower in favour of the combination compared to placebo 
(6548.65 mm × h versus 13052.40 mm × h, mean treatment 
effect − 6503.8 mm × h). Methyl nicotinate alone reached a 
reduction in this variable of 31 % compared with placebo 
(8975.32 mm × h versus 13052.40 mm × h, mean treatment 
effect 4077.1  mm × h). All pair-wise comparisons were 
statistically significant (t-test: p < 0.0001).
The VAS sum score pain on active movement decreased 
from visit 1 to visit 4 by 145.2 mm (88.2 %) in the combi-
nation group, 106.4 mm (67.5 %) in the methyl nicotinate 
group and 62.5 mm (37.8 %) in the placebo group (Fig. 1). 
Back pain at rest clearly decreased from visit 1 to visit 4 
by 45.2 mm (91.5 %) in the combination group, 34.8 mm 
(74 %) in the methyl nicotinate group and 19.3 mm 
(39.2 %) in the placebo group (Fig. 1).
The combination demonstrated superiority to the two 
other treatment arms, while methyl nicotinate displayed 
a considerable effect as well.
Other clinical trials
In an earlier 4-week pilot study, 41 patients with different 
forms of musculoskeletal rheumatism (mainly epicondy-
litis, tendovaginitis and periarthritis) were treated topi-
cally with the same cream as mentioned above (n = 20) 
or with placebo (n = 21) [25]. Efficacy was assessed using 
several pain parameters: tenderness when pressure 
applied, pain at rest and during exercise. With respect 
to “tenderness when pressure applied”, the ointment 
proved superior to placebo in patients with epicondylitis 
and tendovaginitis, but not in patients with periarthritis.
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The effects of dermatological preparations containing 
5 or 10 % of a comfrey root extract (2:7, 50 % ethanol) on 
the process of healing of experimentally induced UV-B 
erythema were studied in 29 volunteers in a controlled 
pharmacological trial. The anti-inflammatory potency of 
the extract was found to be equal to or greater than that of 
diclofenac. A positive correlation could be demonstrated 
between efficacy and the concentration of α-hydroxy caf-
feic acid in the extract, but not for allantoin [7, 26].
Comfrey root has also been used for knee joint injuries 
and non-active gonarthrosis, further in the treatment of 
tendinitis syndrome, insect bites, mastitis, fractures, 
skin inflammation, multiple abscesses of sweat glands, 
gangrenous ecthymas, furuncles, dicubital ulcers and 
chronic varicose ulceration, as prior studies and indi-
vidual case reports reflect [10].
Post-marketing surveillance
Children
In a non-interventional study of a comfrey root extract 
cream containing 35 % of a comfrey root extract (1:2, eth-
anol 60 % (v/v)), the tolerability and efficacy were exam-
ined in 306 children aged 3–12 years [27]. The preparation 
was used for a variety of conditions such as contusions 
(61.4 %), strains (14.1 %), distortions (30.4 %) and other 
indications (6.9 %). Most children applied the ointment 
three times daily (57.8 %), few four times daily (26.1 %) 
or twice a day (13.4  %). Thereby the physicians admin-
istered mostly the same dosages as for adults and chil-
dren of 12 years of age and older. In the overall score of 
the findings pain on palpation, restriction of movement 
and haematoma manifestation (minimum 3, maximum 
15) a notable improvement in the clinical result became 
clear: The initial value of 10.61 fell by 6.18 points or by 
58.3  %. Clear remission or improvement was revealed 
in every individual finding. For all clinical symptoms, 
an improvement of more than 50 % could be calculated. 
The most markedly reduction was in pain at rest (62.6 %), 
restriction of movement (62.0  %) and pain sensitivity 
(61.4 %).
Comfrey cream
In a non-interventional post-marketing surveillance 
study, 163 patients with a mean age of 45.3 years applied 
the same comfrey root extract cream for several condi-
tions, the most frequent being contusions (33.1 %), pain-
ful joint complaints (27.6 %), sprains (26.4 %) and painful 
muscle complaints (23.3  %) [28]. Most patients applied 
the preparation two (38 %) or three (48.5 %) times daily 
and the median duration of treatment was 11.5 days. Dur-
ing the observation period, symptoms of pain at rest and 
during the night, pain during motion, tenderness when 
pressure applied, impaired mobility, painful muscle com-
plaints and swellings improved markedly. Morning stiff-
ness of the joints decreased by 94 % from 17 min initially 
to 1 min. The use of NSAIDs was reduced or discontinued 
by 13.5 % of patients. The physicians assessed global effi-
cacy as excellent in 38.7 % of cases and good in 54.6 %.
Comfrey paste
In a simultaneous surveillance study, 162 patients 
applied a similar preparation, a paste containing 30 % of 
the above-mentioned fluid extract of comfrey roots [29]. 






















































Fig. 1 Results VAS sum 
score––Pain on active stan-
dardised movement
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They as well treated a variety of conditions such as pain-
ful joint complaints (34 %), contusions (26.5 %) or pain-
ful muscle complaints (21.6  %). Most patients applied 
the preparation once (23.5  %) or twice (52.5  %) daily 
and the median duration of treatment was 11.8 days. 
Again, symptoms of pain at rest and pain during move-
ment, impaired mobility, swelling and painful muscle 
complaints improved markedly during the observation 
period. Morning stiffness of investigated joints decreased 
by 90 % from 20 min initially to 2 min. The use of NSAIDs 
was reduced or discontinued by 21 % of patients. Global 
efficacy was assessed by the physicians as excellent in 
65.4 % of cases and good in 32.7 %.
Combination with methyl nicotinate
A cream consisting of a combination of 35 % of comfrey 
root fluid extract and 1.2  % methyl nicotinate is avail-
able in Germany, Luxembourg and Switzerland. Another 
simultaneous non-interventional study included 162 
patients with a mean age of 49.7 years [30]. The mean 
duration of treatment was 12.3 days. Pain at rest and dur-
ing the night was reduced by 45 %, pain during motion by 
47 %, tenderness when pressure applied by 47 %, pain-
ful muscle complaints by 48  % and impaired mobility 
improved by 46 %. In the course of the study, seven non-
serious, resolved adverse events, namely skin reactions 
such as redness or itching, were recorded in four patients.
Safety
Literature on comfrey often focuses on the content of 
pyrrolizidine alkaloids (PA) of the raw plant material. It 
is important to note that fully licensed medicinal prod-
ucts available today contain depleted or PA-free pro-
cessed extracts. In fact, using these approved and safe 
products, pyrrolizidine alkaloids are no longer of clinical 
significance. Still, some authors recommend a restriction 
of the duration of treatment, also with externally applied 
comfrey preparations. In Germany, the restriction limit-
ing application to 4–6 weeks/year applies only to prepa-
rations containing more than 10 µg, but less than 100 µg 
pyrrolizidine alkaloids (daily allowance). The applica-
tion of modern preparations results in far below the 
daily allowance of 10 µg. As a consequence, there are no 
restrictions in Germany on these products as regards the 
duration of treatment [31].
The absence of genotoxic effects was demonstrated 
in the bacterial reverse mutation assay (Ames test) for 
the PA-free liquid extract used in the above-mentioned 
clinical trials and studies [32]. The extract was investi-
gated for its ability to induce gene mutations in Salmo-
nella typhimurium strains TA 98, TA 100, TA 102, TA 1535 
and TA 1537 with and without metabolic activation using 
the mammalian microsomal fraction S9 mix. Reference 
mutagens were used to check the validity of the experi-
ments. The comfrey root extract showed no biologically 
relevant increases in revertant colony numbers of any of 
the five tester strains, neither in the presence nor in the 
absence of metabolic activation. In conclusion, the fluid 
extract was not mutagenic in the bacterial reverse muta-
tion assay.
Conclusion
Today, modern clinical data substantiates the traditional 
topical application of comfrey root preparations. Several 
recent randomised clinical trials confirmed the efficacy 
in the treatment of pain, inflammation and swelling in 
the case of degenerative arthritis, acute myalgia in the 
back, sprains, contusions and strains after sports inju-
ries and accidents, also in children aged 3 years and 
older. Comfrey root is a valuable and rational therapeutic 
option for patients suffering from muscles and joint pain 
[33]. Coming from a herbal, representing rational phyto-
therapy, but combining very good efficacy and safety it 
should be a part of physicians’ standard treatment tool 
box.
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